Kim Sablich
Director/Board Member chez EIGER BIOPHARMACEUTICALS, INC.
Fortune : 3 M $ au 31/03/2024
Profil
Kim Sablich is an Independent Director at Eiger BioPharmaceuticals, Inc. She was previously a Director at AllerGenis LLC from 2018 to 2021, Vice President at GSK Plc from 2015 to 2018, Chief Commercial Officer at Myovant Sciences, Inc. from 2018 to 2020, and Chief Commercial Officer at Myovant Sciences Ltd.
from 2018 to 2020.
She is also currently serving as Executive VP & General Manager-North America at Jazz Pharmaceuticals Plc from 2020 to 2023.
Ms. Sablich received her undergraduate degree from Denison University and her MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/06/2023 | 28 478 ( 0,05% ) | 3 M $ | 31/03/2024 | |
| 20/11/2023 | 200 ( 0,01% ) | 1 001 $ | 31/03/2024 |
Postes actifs de Kim Sablich
| Sociétés | Poste | Début |
|---|---|---|
| EIGER BIOPHARMACEUTICALS, INC. | Director/Board Member | 23/04/2021 |
Anciens postes connus de Kim Sablich
| Sociétés | Poste | Fin |
|---|---|---|
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 31/12/2023 |
AllerGenis LLC
 AllerGenis LLC Data Processing ServicesTechnology Services AllerGenis LLC specializes in detecting and managing life-threatening food allergies. AllerGenis is based in Hatfield, PA, and the CEO of the joint venture company is Jim Garner. The company develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess, and monitor patients with food allergies. AllerGenis owns and operates a CLIA-certified laboratory and is amassing the world's largest database of phenotypic patient data derived from epitope mapping, clinical history, and patient-reported outcomes. The company was founded in 2017 through a collaboration between Genisphere and Hugh Sampson MD of the Icahn School of Medicine at Mount Sinai. | Director/Board Member | 01/04/2021 |
| MYOVANT SCIENCES LTD. | Corporate Officer/Principal | 11/05/2020 |
Myovant Sciences, Inc.
 Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Corporate Officer/Principal | 01/05/2020 |
| GSK PLC | Corporate Officer/Principal | 01/05/2018 |
Formation de Kim Sablich
| Denison University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GSK PLC | Health Technology |
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Health Technology |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
AllerGenis LLC
AllerGenis LLC Data Processing ServicesTechnology Services AllerGenis LLC specializes in detecting and managing life-threatening food allergies. AllerGenis is based in Hatfield, PA, and the CEO of the joint venture company is Jim Garner. The company develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess, and monitor patients with food allergies. AllerGenis owns and operates a CLIA-certified laboratory and is amassing the world's largest database of phenotypic patient data derived from epitope mapping, clinical history, and patient-reported outcomes. The company was founded in 2017 through a collaboration between Genisphere and Hugh Sampson MD of the Icahn School of Medicine at Mount Sinai. | Technology Services |
